Performance Task

Tykerb Assessment
Alex Raschiatore, Brady
Kesterholt.
Cellular Mechanism of action
● HER2 is a tyrosine kinase receptors in the class of erbB (Schroeder, R., Stevens, C., & Sridhar, J., 2014)

● Critical roles in the signal transduction cascade in pathways responsible for cell growth and differentiation
(Schroeder, R., Stevens, C., & Sridhar, J. , 2014)

● Amplification and overexpression of the HER2 encoding oncogene results in unregulated cell proliferation
(Schroeder, R., Stevens, C., & Sridhar, J. , 2014)
○ In an aggressive form of breast cancer known as HER2-positive breast cancer. (Schroeder, R., Stevens, C., &
Sridhar, J. , 2014)
Cellular Mechanism of action

(2019). Retrieved 14 November 2019, from https://www.researchgate.net/figure/Mechanism-of-action-of-lapatinib-eRBB2-homodimerization-

or-heterodimerization-with-other_fig1_259456792
Document A

❖ Credible

❖ Targeted drugs - Herceptin, Avastin, and Tykerb (Document A)

❖ Drug similar to Tykerb are Herceptin (Document A)

❖ Benefits of having similar drugs (Document A)

Document B

❖ Noncredible

❖ Breast examination (Document B)

❖ HER2 not effective by chemotherapy (Document B)

❖ Breast cancer in 1 out of 7 non hereditary link (Document B)

Document C

❖ Credible

❖ Trend of decreased stress (Document C)

❖ Over 8 Week treatment of Tykerb (Document C)

❖ Unlikely correlation between Tykerb and stress levels (Document C)

Document D
❖ Credible

❖ Drug combinations

❖ Higher response to tykerb with the other medication (Document D)

➢ Chemotherapy

❖ Clinic trial (Document D)

Document E

❖ Credible

❖ Tumor decrease with higher dosage (Document E)

❖ Around 40 % decrease in tumor size (Document E)

❖ 1250 mg of Tykerb with chemotherapy was most effective (Document E)

Document F
❖ Not Credible
➢ Biased

❖ Discusses the benefits of herbal medicine as an anti-cancer (Document F)

➢ More cost efficient than pharmaceutical drugs (Document F)
➢ Certain foods have chemopreventive benefits (Document F)

❖ Tykerb not relevant to article

Document G

❖ Credible
➢ Trial done in three phases (Document G)
➢ Results for drug effect prostate (Document G)

❖ Herbal interaction with anti cancer drug (Document G)

❖ No mention of Tykerb
Document H

❖ Ryan forbes
➢ founder of Natural Way (Document H)

❖ Does not support ineffectiveness or harmfulness of St. John Wort (Document H)

❖ Credible
➢ Reliable source of tykerb information
Strengths

❖ Decreased tumor size (Document E)

❖ Already approved by the FDA (Document A)

❖ Can be used in combination with other drugs (Document D)

Weaknesses

❖ Insurances most likely won't cover the cost (Document A)

❖ Drug usually reserved for women who are either allergic to other medications or who have already undergone
treatments with trastuzumab which have failed (Document A)

❖ Combination with chemotherapy to be effective (Document E)

Recommendations

★ Overall, we thought that Dr. Pill should continue their work with Tykerb because the drug overall was shown

to be a strong option itself. For the treatment of breast cancer in patients with an overexpression in the Her2

protein.
References
● Documents A-H

● Schroeder, R., Stevens, C., & Sridhar, J. (2014). Small molecule tyrosine kinase inhibitors of erbb2/her2/neu in the treatment of
aggressive breast cancer. Molecules (basel, Switzerland), 19(9), 15196-212. doi:10.3390/molecules190915196

● (2019). Retrieved 14 November 2019, from https://www.researchgate.net/figure/Mechanism-of-action-of-lapatinib-eRBB2-

homodimerization-or-heterodimerization-with-other_fig1_259456792